Verified peer comparison

MCK vs ABBV

McKesson Corporation compared with AbbVie Inc.. This page compares both source-verified company profiles and does not introduce an unverified price target.

MCK

McKesson Corporation

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

ABBV

AbbVie Inc.

$189.43

Open: --
High: --
Low: --
Market Cap: --

Open stock research

Company-specific comparison

Business exposure

MCK: Health Care Distributors

ABBV: Biotechnology

Upside lens

MCK: Growth in complex medicines can increase distribution, provider-services and data demand. The US Oncology Network and related services can deepen relationships with community practices and manufacturers. Strong cash conversion can fund repurchases and targeted investment in higher-growth health platforms.

ABBV: Continued Skyrizi and Rinvoq adoption is expanding AbbVie's immunology portfolio and replacing revenue lost after Humira's U.S. exclusivity expiry. Growth across Vraylar, Botox Therapeutic, the migraine portfolio, and Vyalev broadens AbbVie's growth base beyond immunology. Regulatory submissions, approvals, and key clinical data readouts expected over the next year could add indications and reinforce the post-Humira portfolio transition.

Risk lens

MCK: Large pharmacy and manufacturer relationships can create contract-renewal and pricing leverage risk. Reimbursement, pricing and distribution reforms can alter volumes, working capital and service economics. Controlled-substance obligations and healthcare compliance failures can create litigation and remediation costs.

ABBV: Humira revenue continues to contract after biosimilar entry, leaving execution on replacement growth products essential to the portfolio transition. Imbruvica declines are weighing on oncology, requiring growth from Venclexta, Elahere, and pipeline assets to offset the mature brand. U.S. drug-pricing policy, including the selection of Botox for Medicare negotiated prices beginning in 2028, could pressure future revenue and margins.